tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

RVMD Stock Latest News

Revolution Medicines: Advancing Late-Stage RAS Inhibitor Pipeline with Pivotal Phase 3 Catalysts Supports Buy Rating
RatingsRevolution Medicines: Advancing Late-Stage RAS Inhibitor Pipeline with Pivotal Phase 3 Catalysts Supports Buy Rating
3d ago
RVMD
Revolution Medicines announces first patient randomized in RASolute 304 trial
PremiumThe Fly
Revolution Medicines announces first patient randomized in RASolute 304 trial
3d ago
RVMD
Accelerated Phase 3 Trial and Strong Enrollment Boost Confidence in Revolution Medicines: Buy Rating Affirmed
PremiumRatings
Accelerated Phase 3 Trial and Strong Enrollment Boost Confidence in Revolution Medicines: Buy Rating Affirmed
7d ago
RVMD
Revolution Medicines: Buy Rating Backed by Promising RASolute 302 Trial and Potential Stock Surge
PremiumRatings
Revolution Medicines: Buy Rating Backed by Promising RASolute 302 Trial and Potential Stock Surge
9d ago
RVMD
Strategic Positioning and Potential of Revolution Medicines in Pancreatic Cancer Treatment
PremiumRatings
Strategic Positioning and Potential of Revolution Medicines in Pancreatic Cancer Treatment
16d ago
RVMD
Promising Outlook for Revolution Medicines: Buy Rating Backed by Pivotal Trials and Market Potential
PremiumRatingsPromising Outlook for Revolution Medicines: Buy Rating Backed by Pivotal Trials and Market Potential
18d ago
RVMD
Revolution Medicines initiated with an Outperform at Wolfe Research
Premium
The Fly
Revolution Medicines initiated with an Outperform at Wolfe Research
1M ago
RVMD
Revolution Medicines’ Q3 2025 Earnings Call Highlights
Premium
Company Announcements
Revolution Medicines’ Q3 2025 Earnings Call Highlights
1M ago
RVMD
Erasca price target raised to $6 from $4 at Stifel
PremiumThe Fly
Erasca price target raised to $6 from $4 at Stifel
1M ago
ERAS
RVMD
Revolution Medicines: Buy Rating Reaffirmed Amid Strategic Developments and Increased Price Target
PremiumRatings
Revolution Medicines: Buy Rating Reaffirmed Amid Strategic Developments and Increased Price Target
1M ago
RVMD
JPMorgan ups Revolution Medicines target, adds to Analyst Focus List
PremiumThe Fly
JPMorgan ups Revolution Medicines target, adds to Analyst Focus List
2M ago
RVMD
Revolution Medicines price target raised to $73 from $72 at H.C. Wainwright
PremiumThe Fly
Revolution Medicines price target raised to $73 from $72 at H.C. Wainwright
2M ago
RVMD
Revolution Medicines Reports Q3 2025 Financial Results
PremiumCompany AnnouncementsRevolution Medicines Reports Q3 2025 Financial Results
2M ago
RVMD
Revolution Medicines: Strategic Advancements and Promising Pipeline in PDAC Treatment Justify Buy Rating
Premium
Ratings
Revolution Medicines: Strategic Advancements and Promising Pipeline in PDAC Treatment Justify Buy Rating
2M ago
RVMD
Revolution Medicines: Promising Growth Trajectory with Strong Financial Health and Strategic Advancements
Premium
Ratings
Revolution Medicines: Promising Growth Trajectory with Strong Financial Health and Strategic Advancements
2M ago
RVMD
Revolution Medicines reiterates FY25 GAAP net loss guidance
PremiumThe Fly
Revolution Medicines reiterates FY25 GAAP net loss guidance
2M ago
RVMD
Revolution Medicines reports Q3 EPS ($1.61), consensus ($1.41)
PremiumThe Fly
Revolution Medicines reports Q3 EPS ($1.61), consensus ($1.41)
2M ago
RVMD
Boeing upgraded, Charter downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Boeing upgraded, Charter downgraded: Wall Street’s top analyst calls
2M ago
BA
ALH
Revolution Medicines initiated with an Outperform at RBC Capital
PremiumThe Fly
Revolution Medicines initiated with an Outperform at RBC Capital
2M ago
RVMD
Revolution Medicines: Promising Oncology Leader with Strategic Advancements and Competitive Edge
PremiumRatingsRevolution Medicines: Promising Oncology Leader with Strategic Advancements and Competitive Edge
2M ago
RVMD
Revolution Medicines Advances RAS(ON) Inhibitor Study in Gastrointestinal Cancers
Premium
Company Announcements
Revolution Medicines Advances RAS(ON) Inhibitor Study in Gastrointestinal Cancers
2M ago
RVMD
Revolution Medicines Advances RAS(ON) Inhibitors in NSCLC Study
Premium
Company Announcements
Revolution Medicines Advances RAS(ON) Inhibitors in NSCLC Study
2M ago
RVMD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >